Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab

Abstract Novel predictive biomarkers are needed to improve patient selection and optimize the use of bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating biomarkers to predict B efficacy and monitor response. Peripheral blood samples collected at baseline, a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giorgia Marisi, Emanuela Scarpi, Alessandro Passardi, Oriana Nanni, Angela Ragazzini, Martina Valgiusti, Andrea Casadei Gardini, Luca Maria Neri, Giovanni Luca Frassineti, Dino Amadori, Paola Ulivi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1aee86c84bb84dbda67d66b5890094d6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1aee86c84bb84dbda67d66b5890094d6
record_format	dspace
spelling	oai:doaj.org-article:1aee86c84bb84dbda67d66b5890094d62021-12-02T12:32:07ZCirculating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab10.1038/s41598-017-01420-02045-2322https://doaj.org/article/1aee86c84bb84dbda67d66b5890094d62017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-01420-0https://doaj.org/toc/2045-2322Abstract Novel predictive biomarkers are needed to improve patient selection and optimize the use of bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating biomarkers to predict B efficacy and monitor response. Peripheral blood samples collected at baseline, at the first clinical evaluation and at progression were available for 129 patients enrolled in the prospective multicentric ITACa trial and randomized to receive FOLFOX4/FOLFIRI (CT) with (64 patients) or without B (65 patients). VEGF-A, eNOS, EPHB4, COX2 and HIF-1α mRNA levels were measured by qRT-PCR. Baseline marker expression levels and their modulation during therapy were analyzed in relation to objective response, progression-free survival and overall survival (OS). VEGF and eNOS expression was significantly correlated in both groups (Spearman’s correlation coefficient = 0.80; P < 0.0001 and 0.75; P < 0.0001, respectively). B-treated patients with >30% reduction in eNOS and VEGF levels from baseline to the first clinical evaluation showed better OS than the others (median OS 31.6 months, 95% CI 21.3–49.5 months and median OS 14.4 months, 95% CI 9.0–22.7 months, respectively, HR 0.38, 95% CI 0.19–0.78, P = 0.008). A reduction in eNOS and VEGF expression from baseline to the first clinical evaluation may indicate a response to B.Giorgia MarisiEmanuela ScarpiAlessandro PassardiOriana NanniAngela RagazziniMartina ValgiustiAndrea Casadei GardiniLuca Maria NeriGiovanni Luca FrassinetiDino AmadoriPaola UliviNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Giorgia Marisi Emanuela Scarpi Alessandro Passardi Oriana Nanni Angela Ragazzini Martina Valgiusti Andrea Casadei Gardini Luca Maria Neri Giovanni Luca Frassineti Dino Amadori Paola Ulivi Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
description	Abstract Novel predictive biomarkers are needed to improve patient selection and optimize the use of bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating biomarkers to predict B efficacy and monitor response. Peripheral blood samples collected at baseline, at the first clinical evaluation and at progression were available for 129 patients enrolled in the prospective multicentric ITACa trial and randomized to receive FOLFOX4/FOLFIRI (CT) with (64 patients) or without B (65 patients). VEGF-A, eNOS, EPHB4, COX2 and HIF-1α mRNA levels were measured by qRT-PCR. Baseline marker expression levels and their modulation during therapy were analyzed in relation to objective response, progression-free survival and overall survival (OS). VEGF and eNOS expression was significantly correlated in both groups (Spearman’s correlation coefficient = 0.80; P < 0.0001 and 0.75; P < 0.0001, respectively). B-treated patients with >30% reduction in eNOS and VEGF levels from baseline to the first clinical evaluation showed better OS than the others (median OS 31.6 months, 95% CI 21.3–49.5 months and median OS 14.4 months, 95% CI 9.0–22.7 months, respectively, HR 0.38, 95% CI 0.19–0.78, P = 0.008). A reduction in eNOS and VEGF expression from baseline to the first clinical evaluation may indicate a response to B.
format	article
author	Giorgia Marisi Emanuela Scarpi Alessandro Passardi Oriana Nanni Angela Ragazzini Martina Valgiusti Andrea Casadei Gardini Luca Maria Neri Giovanni Luca Frassineti Dino Amadori Paola Ulivi
author_facet	Giorgia Marisi Emanuela Scarpi Alessandro Passardi Oriana Nanni Angela Ragazzini Martina Valgiusti Andrea Casadei Gardini Luca Maria Neri Giovanni Luca Frassineti Dino Amadori Paola Ulivi
author_sort	Giorgia Marisi
title	Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
title_short	Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
title_full	Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
title_fullStr	Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
title_full_unstemmed	Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
title_sort	circulating vegf and enos variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/1aee86c84bb84dbda67d66b5890094d6
work_keys_str_mv	AT giorgiamarisi circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab AT emanuelascarpi circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab AT alessandropassardi circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab AT orianananni circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab AT angelaragazzini circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab AT martinavalgiusti circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab AT andreacasadeigardini circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab AT lucamarianeri circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab AT giovannilucafrassineti circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab AT dinoamadori circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab AT paolaulivi circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab
_version_	1718394144434421760

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab

Ejemplares similares